US to phase out OTC asthma inhalers citing environmental concerns – Pharmaceutical Business Review

US to phase out OTC asthma inhalers citing environmental concerns
Pharmaceutical Business Review
The United States Food and Drug Administration (FDA) announced that over-the-counter (OTC) asthma inhaler, Primatene Mist, containing chlorofluorocarbons (CFCs) will be taken off the US market from 31 December. The CFCs present in the product deplete
Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST MarketWatch (press release)

all 13 news articles »

View full post on asthma – Google News